Document is current
Any future updates will be listed below
-
Authors
Ruotsalainen, Jarno https://orcid.org/0000-0003-1056-3838
Lehmus, Leena https://orcid.org/0009-0004-0494-3900
Putkonen, Mervi
Lievonen, Juha
Kallio, Alvar
Raittinen, Paavo https://orcid.org/0000-0003-4207-8415
Summanen, Milla https://orcid.org/0000-0003-3843-2741
Kosunen, Mikko https://orcid.org/0000-0002-0908-5288
Korhonen, Maarit Jaana https://orcid.org/0000-0002-2953-4757
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 6 September 2023
Accepted: 28 November 2023
First Online: 12 December 2023
Declarations
:
: This article does not contain any studies with human participants performed by any of the authors.This register-based study was approved by each register holder.
: LL and MK are employed by Pfizer Oy and own Pfizer stocks. MS is a former employee of Pfizer Oy. MP declares honoraria for lectures from and membership on advisory boards with BMS, Janssen, Pfizer and Sanofi, and consultancy for Janssen and Pfizer. JL has received consultancy fees from Bristol-Myers Squibb. JR, MJK, PR and AK are employees of Oriola Finland Oy, which received funding from Pfizer Oy in connection with the development of this manuscript.
